Acrivon Therapeutics To Deliver Three Presentations At The AACR-NCI-EORTC Highlighting Advances From Its Proprietary Generative Phosphoproteomics AP3 Platform For Developing Precision Medicines

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development

Favorable ACR-2316 preclinical data, demonstrating its differentiated and superior pathway effects versus benchmark WEE1 and PKMYT1 inhibitors consistent with prior observations

Company to report initial clinical data for ACR-2316 in AP3-predicted tumor types later this year; clinical activity and confirmed partial response observed during dose escalation 

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today announced three presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place from October 22-26, 2025 in Boston, MA.

"At this year's AACR-NCI-EORTC meeting, we are excited to present a powerful set of posters that illustrate our unique and data-driven approach to precision medicine development and generative AI drug discovery," said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon and president and CEO of the company´s research subsidiary Acrivon AB in Lund, Sweden. "Our presentations feature our innovative AP3 KaiSR ensemble model, which expands our ability to rationally design drugs optimized for desirable activity on biologically relevant pathways in the intact cell, as well as robust mechanistic data for ACR-2316 including pathway analyses that underpin the superior preclinical activity of the asset. We look forward to sharing initial clinical data from our Phase 1 study of ACR-2316 later this year, building upon the disclosed clinical activity already observed across AP3-predicted solid tumor types during the dose-escalation phase."